Exact Mass: 435.22569080000005
Exact Mass Matches: 435.22569080000005
Found 76 metabolites which its exact mass value is equals to given mass value 435.22569080000005
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Fosinoprilat
C23H34NO5P (435.2174484000001)
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents
Valsartan
Valsartan is an angiotensin-receptor blocker (ARB) that may be used to treat a variety of cardiac conditions including hypertension, diabetic nephropathy and heart failure. Valsartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Valsartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease. C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09C - Angiotensin ii receptor blockers (arbs), plain > C09CA - Angiotensin ii receptor blockers (arbs), plain C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist D057911 - Angiotensin Receptor Antagonists > D047228 - Angiotensin II Type 1 Receptor Blockers COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Valsartan (CGP 48933) is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research[1].
Cadabicine
C25H29N3O4 (435.21579540000005)
Cadabicine is found in fruits. Cadabicine is an alkaloid from the stem bark of the famine food Cadaba farinosa (luquata sigmama). Alkaloid from the stem bark of the famine food Cadaba farinosa (luquata sigmama). Cadabicine is found in fruits.
N-Pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
Valsartan
C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09C - Angiotensin ii receptor blockers (arbs), plain > C09CA - Angiotensin ii receptor blockers (arbs), plain C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist D057911 - Angiotensin Receptor Antagonists > D047228 - Angiotensin II Type 1 Receptor Blockers COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 1075 CONFIDENCE standard compound; INTERNAL_ID 1112 CONFIDENCE standard compound; INTERNAL_ID 8608 CONFIDENCE standard compound; EAWAG_UCHEM_ID 2583 INTERNAL_ID 1112; CONFIDENCE standard compound Valsartan (CGP 48933) is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research[1].
Phe Gly Gly Arg
C19H29N7O5 (435.22300640000003)
Phe Gly Arg Gly
C19H29N7O5 (435.22300640000003)
Phe Arg Gly Gly
C19H29N7O5 (435.22300640000003)
Gly Phe Gly Arg
C19H29N7O5 (435.22300640000003)
Gly Phe Arg Gly
C19H29N7O5 (435.22300640000003)
Gly Gly Phe Arg
C19H29N7O5 (435.22300640000003)
Gly Gly Arg Phe
C19H29N7O5 (435.22300640000003)
Gly Arg Phe Gly
C19H29N7O5 (435.22300640000003)
Gly Arg Gly Phe
C19H29N7O5 (435.22300640000003)
Lys Ser Thr Thr
Lys Thr Ser Thr
Lys Thr Thr Ser
Arg Phe Gly Gly
C19H29N7O5 (435.22300640000003)
Arg Gly Phe Gly
C19H29N7O5 (435.22300640000003)
Arg Gly Gly Phe
C19H29N7O5 (435.22300640000003)
Ser Lys Thr Thr
Ser Thr Lys Thr
Ser Thr Thr Lys
Thr Lys Ser Thr
Thr Lys Thr Ser
Thr Ser Lys Thr
Thr Ser Thr Lys
Thr Thr Lys Ser
Thr Thr Ser Lys
Cadabicine
C25H29N3O4 (435.21579540000005)
DANSYL-GAMMA-AMINO-N-BUTYRIC ACID CYCLOHEXYLAMMONIUM SALT
C22H33N3O4S (435.2191658000001)
(22Z)-4-hydroxy-2-oxa-11,16,20-triazatricyclo[22.2.2.13,7]nonacosa-1(26),3,5,7(29),8,22,24,27-octaene-10,21-dione
C25H29N3O4 (435.21579540000005)
N,N-dibutyl-2-[[2-(1,3-dioxo-2-isoindolyl)-1-oxoethyl]amino]benzamide
C25H29N3O4 (435.21579540000005)
2-Cyclopentyl-4-[1,4-dioxa-8-azaspiro[4.5]decan-8-yl(oxo)methyl]-9-methyl-1-pyrido[3,4-b]indolone
C25H29N3O4 (435.21579540000005)
N-(2-furanylmethyl)-N-[4-methyl-2-(4-methyl-1-piperazinyl)-6-quinolinyl]butanediamide
(1S,9R,10R,11R)-12-(cyclobutanecarbonyl)-10-(hydroxymethyl)-N,N-dimethyl-6-oxo-5-phenyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
C25H29N3O4 (435.21579540000005)
[(1S)-1-(cyclopropylmethyl)-2-[(2-fluorophenyl)methyl]-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol
1-[(2S,3R)-2-(hydroxymethyl)-1-[4-oxanyl(oxo)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]-2-(3-pyridinyl)ethanone
C25H29N3O4 (435.21579540000005)
[(1R)-1-(cyclopropylmethyl)-2-[(2-fluorophenyl)methyl]-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol
(3R,6aS,8S,10aS)-8-[2-(cyclobutylamino)-2-oxoethyl]-N-(4-fluorophenyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(1R,9S,10S,11S)-12-(cyclobutanecarbonyl)-10-(hydroxymethyl)-N,N-dimethyl-6-oxo-5-phenyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
C25H29N3O4 (435.21579540000005)
1-[(1S)-1-(hydroxymethyl)-7-methoxy-2-[(2-methoxyphenyl)methyl]-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]ethanone
C25H29N3O4 (435.21579540000005)
1-[(2S,3S)-2-(hydroxymethyl)-1-[4-oxanyl(oxo)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]-2-(3-pyridinyl)ethanone
C25H29N3O4 (435.21579540000005)
1-[(2R,3R)-2-(hydroxymethyl)-1-[4-oxanyl(oxo)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]-2-(3-pyridinyl)ethanone
C25H29N3O4 (435.21579540000005)
1-[(1R)-1-(hydroxymethyl)-7-methoxy-2-[(2-methoxyphenyl)methyl]-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]ethanone
C25H29N3O4 (435.21579540000005)
2-[Bis(phenylmethyl)amino]-1-(4-phenylmethoxyphenyl)-1-propanone
N-Pentanoyl-N-{[2-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
7-[2-(5-amino-2,2-dimethylchromen-6-yl)-2-oxoethyl]-9-hydroxy-11-(prop-1-en-2-yl)-5,8-diazatricyclo[5.2.2.0¹,⁵]undec-8-en-6-one
C25H29N3O4 (435.21579540000005)
(22z)-2-oxa-11,16,20-triazatricyclo[22.2.2.1³,⁷]nonacosa-1(26),3(29),4,6,8,10,20,22,24,27-decaene-4,10,21-triol
C25H29N3O4 (435.21579540000005)
(8e,22e)-2-oxa-11,16,20-triazatricyclo[22.2.2.1³,⁷]nonacosa-1(26),3(29),4,6,8,10,20,22,24,27-decaene-4,10,21-triol
C25H29N3O4 (435.21579540000005)
(1r,7r,11r)-7-[2-(5-amino-2,2-dimethylchromen-6-yl)-2-oxoethyl]-9-hydroxy-11-(prop-1-en-2-yl)-5,8-diazatricyclo[5.2.2.0¹,⁵]undec-8-en-6-one
C25H29N3O4 (435.21579540000005)
(3s,5s)-5-[(3s,8s,9r,9as)-8-hydroxy-9-[(2s)-1-(5-hydroxy-3-methoxy-4-methylfuran-2-yl)-1-oxopropan-2-yl]-octahydro-1h-pyrrolo[1,2-a]azepin-3-yl]-3-methyloxolan-2-one
C23H33NO7 (435.22569080000005)
2-oxa-11,16,20-triazatricyclo[22.2.2.1³,⁷]nonacosa-1(26),3(29),4,6,8,10,20,22,24,27-decaene-4,10,21-triol
C25H29N3O4 (435.21579540000005)
(5z)-5-{1-hydroxy-2-[8-hydroxy-3-(4-methyl-5-oxooxolan-2-yl)-octahydro-1h-pyrrolo[1,2-a]azepin-9-yl]propylidene}-4-methoxy-3-methylfuran-2-one
C23H33NO7 (435.22569080000005)